Cancer Targeted Technology (CTT) is a biotechnology company working on small molecular weight enzyme inhibitors with unique and unexploited imaging and drug delivery properties. The Company's first product, CTT-54, recognizes the molecular target, Prostate Specific Membrane Antigen, with unique and unexploited binding characteristics. PSMA is an exceptional FDA-approved biomarker for prostate cancer and is expressed on close to 100% of prostate tumors with increase in expression correlated with disease progression and low expression in normal tissue. PSMA is also expressed on the new blood vessels of a variety of non-prostatic solid malignancies, making the utility and broader market for CTT-54, significant.The firm's development pipeline includes: 1. Diagnostic imaging of prostate cancer; 2. Detection of circulating tumor cells; 3. Targeted delivery of radio- photo- and chemotherapeutics
